Medicamen Biotech Profile
Key Indicators
- Authorised Capital ₹ 15.00 Cr
as on 24-10-2024
- Paid Up Capital ₹ 12.71 Cr
as on 24-10-2024
- Company Age 30 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 65.73 Cr
as on 24-10-2024
- Satisfied Charges ₹ 42.09 Cr
as on 24-10-2024
- Revenue 19.78%
(FY 2023)
- Profit 0.64%
(FY 2023)
- Ebitda 2.51%
(FY 2023)
- Net Worth 30.91%
(FY 2023)
- Total Assets 22.63%
(FY 2023)
About Medicamen Biotech
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 531146 and on the National Stock Exchange(NSE) under MEDICAMEQ.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 15.00 Cr and a paid-up capital of Rs 12.71 Cr.
The company currently has active open charges totaling ₹65.73 Cr. The company has closed loans amounting to ₹42.09 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Medicamen Biotech Limited India are Rajesh Madan as Ceo, Pratap Rawat as Cfo, and Parul Choudhary as Company Secretary. Sanjay Bansal, Rahul Bishnoi, Suresh Singh, and Seven other members serve as directors at the Company.
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Medicamen Biotech?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Madan  | CEO | Current | |
| Pratap Rawat | CFO | Current | |
| Parul Choudhary | Company Secretary | Current |
Board Members(10)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Suresh Singh | Director | 31-Dec-2015 | Current |
| Rahul Bishnoi | Director | 31-Dec-2015 | Current |
| Ashwani Sharma | Director | 31-Dec-2015 | Current |
| Sanjay Bansal | Director | 01-Dec-1994 | Current |
| Harish Pande | Director | 31-Dec-2015 | Current |
| Arun Kumar | Director | 27-Feb-2016 | Current |
Financial Performance and Corporate Structure Insights of Medicamen Biotech.
Medicamen Biotech Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 19.78% increase. The company also saw a slight improvement in profitability, with a 0.64% increase in profit. The company's net worth Soared by an impressive increase of 30.91%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medicamen Biotech?
In 2022, Medicamen Biotech had a promoter holding of 43.60% and a public holding of 56.40%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Shivalik Rasayan LimitedActive 45 years 9 monthsSanjay Bansal, Rahul Bishnoi and 8 more are mutual person
Medicamen Life Sciences Private LimitedActive 2 years 4 monthsRahul Bishnoi and Ashwani Sharma are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 10 May 2023 | ₹3.50 M | Open |
Citi Bank N.A. Creation Date: 19 Mar 2021 | ₹20.00 Cr | Open |
Others Creation Date: 30 Jan 2021 | ₹1.20 Cr | Open |
How Many Employees Work at Medicamen Biotech?
Medicamen Biotech has a workforce of 406 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medicamen Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medicamen Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
